Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMethallenestril
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Methallenestril
- Accession Number
- DB13143
- Type
- Small Molecule
- Groups
- Experimental
- Description
- Not Available
- Structure
Structure for DB13143 (Methallenestril)
- Synonyms
- b-ethyl-6-methoxy-a,a-dimethyl-2-naphthalenepropionic acid
- International/Other Brands
- Vallestril
- Categories
- UNII
- XL025389JS
- CAS number
- 517-18-0
- Weight
- Average: 286.371
Monoisotopic: 286.156894568 - Chemical Formula
- C18H22O3
- InChI Key
- KHLJKRBMZVNZOC-MRXNPFEDSA-N
- InChI
- InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)/t16-/m1/s1
- IUPAC Name
- (3R)-3-(6-methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
- SMILES
- CC[C@H](C1=CC=C2C=C(OC)C=CC2=C1)C(C)(C)C(O)=O
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Methallenestril. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril. Experimental, Illicit 5-androstenedione The serum concentration of 5-androstenedione can be increased when it is combined with Methallenestril. Experimental, Illicit Abciximab Methallenestril may decrease the anticoagulant activities of Abciximab. Approved Aceclofenac Aceclofenac may increase the thrombogenic activities of Methallenestril. Approved, Investigational Acenocoumarol Methallenestril may decrease the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid Acetylsalicylic acid may increase the thrombogenic activities of Methallenestril. Approved, Vet Approved Alclometasone The serum concentration of Alclometasone can be increased when it is combined with Methallenestril. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Methallenestril. Experimental, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methallenestril. Experimental, Investigational Amcinonide The serum concentration of Amcinonide can be increased when it is combined with Methallenestril. Approved Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Methallenestril. Approved Aminosalicylic Acid Aminosalicylic Acid may increase the thrombogenic activities of Methallenestril. Approved Anastrozole The therapeutic efficacy of Anastrozole can be decreased when used in combination with Methallenestril. Approved, Investigational Ancrod Methallenestril may decrease the anticoagulant activities of Ancrod. Approved, Investigational Androstenedione The serum concentration of Androstenedione can be increased when it is combined with Methallenestril. Experimental, Illicit Anecortave The serum concentration of Anecortave can be increased when it is combined with Methallenestril. Investigational anecortave acetate The serum concentration of anecortave acetate can be increased when it is combined with Methallenestril. Investigational Anthrax immune globulin human Methallenestril may increase the thrombogenic activities of Anthrax immune globulin human. Approved Antipyrine Antipyrine may increase the thrombogenic activities of Methallenestril. Approved, Investigational Antithrombin III human Methallenestril may decrease the anticoagulant activities of Antithrombin III human. Approved Antrafenine Antrafenine may increase the thrombogenic activities of Methallenestril. Approved Apixaban Methallenestril may decrease the anticoagulant activities of Apixaban. Approved Ardeparin Methallenestril may decrease the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Methallenestril may decrease the anticoagulant activities of Argatroban. Approved, Investigational Ascorbic acid The serum concentration of Methallenestril can be increased when it is combined with Vitamin C. Approved, Nutraceutical Atamestane The serum concentration of Atamestane can be increased when it is combined with Methallenestril. Investigational Balsalazide Balsalazide may increase the thrombogenic activities of Methallenestril. Approved, Investigational Becaplermin Methallenestril may decrease the anticoagulant activities of Becaplermin. Approved, Investigational Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Methallenestril. Approved, Vet Approved Bivalirudin Methallenestril may decrease the anticoagulant activities of Bivalirudin. Approved, Investigational Bromfenac Bromfenac may increase the thrombogenic activities of Methallenestril. Approved Bufexamac Bufexamac may increase the thrombogenic activities of Methallenestril. Approved, Experimental Caffeine The serum concentration of Caffeine can be increased when it is combined with Methallenestril. Approved Capromab pendetide Methallenestril may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Capsaicin Capsaicin may increase the thrombogenic activities of Methallenestril. Approved Carprofen Carprofen may increase the thrombogenic activities of Methallenestril. Approved, Vet Approved, Withdrawn Celecoxib Celecoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational Certoparin Methallenestril may decrease the anticoagulant activities of Certoparin. Approved, Investigational Chenodeoxycholic acid The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Methallenestril. Approved Chlorphenesin Chlorphenesin may increase the thrombogenic activities of Methallenestril. Approved, Vet Approved, Withdrawn Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the thrombogenic activities of Methallenestril. Approved Ciclesonide The serum concentration of Ciclesonide can be increased when it is combined with Methallenestril. Approved, Investigational Cimicoxib Cimicoxib may increase the thrombogenic activities of Methallenestril. Investigational Cisplatin Cisplatin may increase the thrombogenic activities of Methallenestril. Approved Clobetasol The serum concentration of Clobetasol can be increased when it is combined with Methallenestril. Approved, Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be increased when it is combined with Methallenestril. Approved Clobetasone The serum concentration of Clobetasone can be increased when it is combined with Methallenestril. Approved Clocortolone The serum concentration of Clocortolone can be increased when it is combined with Methallenestril. Approved Clodronic Acid Clodronic Acid may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Vet Approved Conestat alfa Methallenestril may increase the thrombogenic activities of Conestat alfa. Approved, Investigational Cortexolone 17α-propionate The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Methallenestril. Investigational Corticosterone The serum concentration of Corticosterone can be increased when it is combined with Methallenestril. Experimental Cortisone acetate The serum concentration of Cortisone acetate can be increased when it is combined with Methallenestril. Approved, Investigational Dabigatran etexilate Methallenestril may decrease the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Methallenestril may decrease the anticoagulant activities of Dalteparin. Approved Danaparoid Methallenestril may decrease the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Methallenestril may decrease the anticoagulant activities of Darexaban. Investigational Deflazacort The serum concentration of Deflazacort can be increased when it is combined with Methallenestril. Approved, Investigational Desirudin Methallenestril may decrease the anticoagulant activities of Desirudin. Approved Desonide The serum concentration of Desonide can be increased when it is combined with Methallenestril. Approved, Investigational Desoximetasone The serum concentration of Desoximetasone can be increased when it is combined with Methallenestril. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Methallenestril. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Methallenestril. Experimental, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Methallenestril. Vet Approved Dexibuprofen Dexibuprofen may increase the thrombogenic activities of Methallenestril. Approved, Investigational Dexketoprofen Dexketoprofen may increase the thrombogenic activities of Methallenestril. Approved, Investigational Dextran Methallenestril may decrease the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dicoumarol Methallenestril may decrease the anticoagulant activities of Dicoumarol. Approved Diflorasone The serum concentration of Diflorasone can be increased when it is combined with Methallenestril. Approved Diflunisal Diflunisal may increase the thrombogenic activities of Methallenestril. Approved, Investigational Difluocortolone The serum concentration of Difluocortolone can be increased when it is combined with Methallenestril. Approved, Investigational, Withdrawn Difluprednate The serum concentration of Difluprednate can be increased when it is combined with Methallenestril. Approved Drospirenone Drospirenone may increase the thrombogenic activities of Methallenestril. Approved Droxicam Droxicam may increase the thrombogenic activities of Methallenestril. Withdrawn Dyphylline The serum concentration of Dyphylline can be increased when it is combined with Methallenestril. Approved Edetic Acid Methallenestril may decrease the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Methallenestril may decrease the anticoagulant activities of Edoxaban. Approved Enoxaparin Methallenestril may decrease the anticoagulant activities of Enoxaparin. Approved Equilenin The serum concentration of Equilenin can be increased when it is combined with Methallenestril. Experimental Equilin The serum concentration of Equilin can be increased when it is combined with Methallenestril. Approved Estrone The serum concentration of Estrone can be increased when it is combined with Methallenestril. Approved Estrone sulfate The serum concentration of Estrone sulfate can be increased when it is combined with Methallenestril. Approved Etanercept Etanercept may increase the thrombogenic activities of Methallenestril. Approved, Investigational Ethyl biscoumacetate Methallenestril may decrease the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac Etodolac may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Vet Approved Etoricoxib Etoricoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational Exemestane The therapeutic efficacy of Exemestane can be decreased when used in combination with Methallenestril. Approved, Investigational Fenoprofen Fenoprofen may increase the thrombogenic activities of Methallenestril. Approved Ferulic acid Methallenestril may decrease the anticoagulant activities of Ferulic acid. Experimental Fluasterone The serum concentration of Fluasterone can be increased when it is combined with Methallenestril. Investigational Fludrocortisone The serum concentration of Fludrocortisone can be increased when it is combined with Methallenestril. Approved, Investigational Fluindione Methallenestril may decrease the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone The serum concentration of Flumethasone can be increased when it is combined with Methallenestril. Approved, Vet Approved Flunisolide The serum concentration of Flunisolide can be increased when it is combined with Methallenestril. Approved, Investigational Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Methallenestril. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be increased when it is combined with Methallenestril. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be increased when it is combined with Methallenestril. Approved, Withdrawn Fluorometholone The serum concentration of Fluorometholone can be increased when it is combined with Methallenestril. Approved, Investigational Fluprednidene The serum concentration of Fluprednidene can be increased when it is combined with Methallenestril. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be increased when it is combined with Methallenestril. Approved Flurandrenolide The serum concentration of Flurandrenolide can be increased when it is combined with Methallenestril. Approved Flurbiprofen Flurbiprofen may increase the thrombogenic activities of Methallenestril. Approved, Investigational Fluticasone The serum concentration of Fluticasone can be increased when it is combined with Methallenestril. Approved, Experimental, Investigational Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Methallenestril. Approved Fondaparinux Methallenestril may decrease the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Formestane The serum concentration of Formestane can be increased when it is combined with Methallenestril. Approved, Investigational, Withdrawn Gabexate Methallenestril may decrease the anticoagulant activities of Gabexate. Investigational Ganciclovir The serum concentration of Ganciclovir can be increased when it is combined with Methallenestril. Approved, Investigational Ginseng Ginseng may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Nutraceutical Halcinonide The serum concentration of Halcinonide can be increased when it is combined with Methallenestril. Approved, Investigational, Withdrawn HE3286 The serum concentration of HE3286 can be increased when it is combined with Methallenestril. Investigational Heparin Methallenestril may decrease the anticoagulant activities of Heparin. Approved, Investigational Human C1-esterase inhibitor Methallenestril may increase the thrombogenic activities of Human C1-esterase inhibitor. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methallenestril. Approved, Investigational Icosapent Icosapent may increase the thrombogenic activities of Methallenestril. Approved, Nutraceutical Idraparinux Methallenestril may decrease the anticoagulant activities of Idraparinux. Investigational Indomethacin Indomethacin may increase the thrombogenic activities of Methallenestril. Approved, Investigational Istaroxime The serum concentration of Istaroxime can be increased when it is combined with Methallenestril. Investigational Ketoprofen Ketoprofen may increase the thrombogenic activities of Methallenestril. Approved, Vet Approved Lenalidomide Methallenestril may increase the thrombogenic activities of Lenalidomide. Approved Lepirudin Methallenestril may decrease the anticoagulant activities of Lepirudin. Approved Letaxaban Methallenestril may decrease the anticoagulant activities of Letaxaban. Investigational Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Methallenestril. Approved Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Methallenestril. Approved, Vet Approved Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Methallenestril. Approved Lornoxicam Lornoxicam may increase the thrombogenic activities of Methallenestril. Approved, Investigational Loteprednol The serum concentration of Loteprednol can be increased when it is combined with Methallenestril. Approved Lumiracoxib Lumiracoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational Magnesium salicylate Magnesium salicylate may increase the thrombogenic activities of Methallenestril. Approved ME-609 The serum concentration of ME-609 can be increased when it is combined with Methallenestril. Investigational Meclofenamic acid Meclofenamic acid may increase the thrombogenic activities of Methallenestril. Approved, Vet Approved Medrysone The serum concentration of Medrysone can be increased when it is combined with Methallenestril. Approved Mefenamic acid Mefenamic acid may increase the thrombogenic activities of Methallenestril. Approved Melagatran Methallenestril may decrease the anticoagulant activities of Melagatran. Experimental Melengestrol The serum concentration of Melengestrol can be increased when it is combined with Methallenestril. Vet Approved Meloxicam Meloxicam may increase the thrombogenic activities of Methallenestril. Approved, Vet Approved Mesalazine Mesalazine may increase the thrombogenic activities of Methallenestril. Approved Mometasone The serum concentration of Mometasone can be increased when it is combined with Methallenestril. Approved, Vet Approved Morniflumate Morniflumate may increase the thrombogenic activities of Methallenestril. Approved Nabumetone Nabumetone may increase the thrombogenic activities of Methallenestril. Approved Nadroparin Methallenestril may decrease the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Methallenestril may decrease the anticoagulant activities of Nafamostat. Approved, Investigational NCX 1022 The serum concentration of NCX 1022 can be increased when it is combined with Methallenestril. Investigational Nepafenac Nepafenac may increase the thrombogenic activities of Methallenestril. Approved, Investigational Niflumic Acid Niflumic Acid may increase the thrombogenic activities of Methallenestril. Approved Nimesulide Nimesulide may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Withdrawn Oleoyl-estrone The serum concentration of Oleoyl-estrone can be increased when it is combined with Methallenestril. Investigational Ospemifene The risk or severity of adverse effects can be increased when Methallenestril is combined with Ospemifene. Approved, Investigational Otamixaban Methallenestril may decrease the anticoagulant activities of Otamixaban. Investigational Oxaprozin Oxaprozin may increase the thrombogenic activities of Methallenestril. Approved Paramethasone The serum concentration of Paramethasone can be increased when it is combined with Methallenestril. Approved Parecoxib Parecoxib may increase the thrombogenic activities of Methallenestril. Approved Pentaerythritol Tetranitrate Methallenestril may decrease the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Methallenestril may decrease the anticoagulant activities of Pentosan Polysulfate. Approved Phenindione Methallenestril may decrease the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Methallenestril may decrease the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone Phenylbutazone may increase the thrombogenic activities of Methallenestril. Approved, Vet Approved Piroxicam Piroxicam may increase the thrombogenic activities of Methallenestril. Approved, Investigational Pomalidomide Pomalidomide may increase the thrombogenic activities of Methallenestril. Approved Potassium Citrate Methallenestril may decrease the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Methallenestril. Approved, Investigational, Nutraceutical Prasterone sulfate The serum concentration of Prasterone sulfate can be increased when it is combined with Methallenestril. Investigational Prednicarbate The serum concentration of Prednicarbate can be increased when it is combined with Methallenestril. Approved, Investigational Prednisone The serum concentration of Prednisone can be increased when it is combined with Methallenestril. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be increased when it is combined with Methallenestril. Approved, Experimental, Investigational Protein C Methallenestril may decrease the anticoagulant activities of Protein C. Approved Protein S human Methallenestril may decrease the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Methallenestril may decrease the anticoagulant activities of Protocatechualdehyde. Approved Resveratrol Resveratrol may increase the thrombogenic activities of Methallenestril. Approved, Experimental, Investigational Reviparin Methallenestril may decrease the anticoagulant activities of Reviparin. Approved, Investigational Rimexolone The serum concentration of Rimexolone can be increased when it is combined with Methallenestril. Approved Rivaroxaban Methallenestril may decrease the anticoagulant activities of Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Withdrawn Ropinirole Methallenestril may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. Approved, Investigational Salsalate Salsalate may increase the thrombogenic activities of Methallenestril. Approved Seliciclib Seliciclib may increase the thrombogenic activities of Methallenestril. Investigational Sodium Citrate Methallenestril may decrease the anticoagulant activities of Sodium Citrate. Approved, Investigational Somatotropin The therapeutic efficacy of Somatotropin can be decreased when used in combination with Methallenestril. Approved, Investigational Sulodexide Methallenestril may decrease the anticoagulant activities of Sulodexide. Approved, Investigational Suprofen Suprofen may increase the thrombogenic activities of Methallenestril. Approved, Withdrawn Talniflumate Talniflumate may increase the thrombogenic activities of Methallenestril. Approved Tenoxicam Tenoxicam may increase the thrombogenic activities of Methallenestril. Approved Thalidomide Methallenestril may increase the thrombogenic activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The serum concentration of Theophylline can be increased when it is combined with Methallenestril. Approved Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Methallenestril. Approved Tiaprofenic acid Tiaprofenic acid may increase the thrombogenic activities of Methallenestril. Approved Tipranavir Methallenestril may increase the dermatologic adverse activities of Tipranavir. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be increased when it is combined with Methallenestril. Approved, Withdrawn Tolmetin Tolmetin may increase the thrombogenic activities of Methallenestril. Approved Triamcinolone The serum concentration of Triamcinolone can be increased when it is combined with Methallenestril. Approved, Vet Approved Troxerutin Methallenestril may decrease the anticoagulant activities of Troxerutin. Investigational Ulobetasol The serum concentration of Ulobetasol can be increased when it is combined with Methallenestril. Approved Ursodeoxycholic acid The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Methallenestril. Approved, Investigational Valaciclovir The serum concentration of Valaciclovir can be increased when it is combined with Methallenestril. Approved, Investigational Valdecoxib Valdecoxib may increase the thrombogenic activities of Methallenestril. Approved, Investigational, Withdrawn Warfarin Methallenestril may decrease the anticoagulant activities of Warfarin. Approved Ximelagatran Methallenestril may decrease the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 59084697
- PubChem Substance
- 347829260
- ChemSpider
- 34995295
- Wikipedia
- Methallenestril
- ATC Codes
- G03CC03 — Methallenestril
- G03CC — Estrogens, combinations with other drugs
- G03C — ESTROGENS
- G03 — SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
- G — GENITO URINARY SYSTEM AND SEX HORMONES
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00102 mg/mL ALOGPS logP 4.69 ALOGPS logP 4.72 ChemAxon logS -5.4 ALOGPS pKa (Strongest Acidic) 4.53 ChemAxon pKa (Strongest Basic) -4.8 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 46.53 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 83.11 m3·mol-1 ChemAxon Polarizability 32.23 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Naphthalenes
- Sub Class
- Not Available
- Direct Parent
- Naphthalenes
- Alternative Parents
- Anisoles / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Naphthalene / Phenol ether / Anisole / Alkyl aryl ether / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- Not Available
Drug created on November 04, 2016 15:36 / Updated on August 02, 2018 06:48